Presentation is loading. Please wait.

Presentation is loading. Please wait.

The Changing Regulatory Environment for Industry Support The accreditation bodies’ point of view. Ian Starke (UK)

Similar presentations


Presentation on theme: "The Changing Regulatory Environment for Industry Support The accreditation bodies’ point of view. Ian Starke (UK)"— Presentation transcript:

1 The Changing Regulatory Environment for Industry Support The accreditation bodies’ point of view. Ian Starke (UK)

2 Competing Interests Vice-chair Academy of Medical Royal Colleges Directors of CPD committee No commercial affiliations

3 Learning objectives To know about the proposals for medical revalidation in the UK To understand the effect that these proposals may have on the accreditation of CME/CPD activities To appreciate the importance of industry’s commitment to quality CME/CPD

4 Overview Medical revalidation in the UK The medical regulator’s review of CPD The industry regulator’s guidelines for commercial support The view of the accrediting bodies An example for discussion.

5 Regulatory Structures in the UK Department of Health UK Government General Medical Council (GMC) Revalidation Support Team (RST) Responsible Officer Appraiser Doctor Royal Colleges (the N.A.A.)

6 Medical Revalidation in the UK Revalidation is the means by which, every five years, licensed doctors will demonstrate that they remain up to date and fit to practice (GMC 2011). “The more that [CPD] credits can encompass the value of the learning and not simply the time spent engaged in CPD, the more it will be valued by doctors and the better a measure it will be of their CPD activities” (CMO 2008).

7 The Revalidation Process Annual appraisal Supporting information Responsible Officer X 5 Personal Development Plan CPD Recommendation to GMC Clinical Governance information Professional excellence.

8 Lord Patel and the GMC (2010) The regulator should, therefore, be extremely cautious before seeking to intervene directly in CPD through application of prescriptive requirements which may add little or no value and put effective practice at risk. The GMC should re-examine how the regulatory role in CPD should be exercised so as to support doctors in meeting the requirements of revalidation and providing high quality care for their patients.

9 Review of the GMC’s Role in Doctors’ CPD: final report (2011) A continuing learning process, outside formal undergraduate and postgraduate training, which enables doctors to maintain and improve their performance across all areas of their medical practice through the development of knowledge, skills, attitudes and behaviours. uk.org/Final_Report_on_review_of_CPD_14_Oct_2011_web_ version.pdf_448

10 Review of the GMC’s Role in Doctors’ CPD: final report (2011) GMC: – Will not dictate content of individual CPD – Will not dictate a minimum number of hours – Quality assurance of activities may be carried out by Colleges / Faculties The individual is responsible for ensuring quality and value for money The effectiveness of the CPD activity should be discussed at appraisal.

11 ACADEMY STANDARDS AND CRITERIA

12 Draft Standards and Criteria Clearly defined target audience Clearly defined learning aims / objectives Programme has scientific or educational content only Delivery methods appropriate to the learning aims Supporting information clear and relevant

13 Draft Standards and Criteria Expertise of Faculty appropriate for the programme No influence or bias by commercial interests The feedback process must include: – Whether the learning objectives were met – Presence or absence of bias Compliance with legislative and ethical requirements

14 OTHER REGULATORY ISSUES

15 Association of the British Pharmaceutical Industry CODE OF PRACTICE for the PHARMACEUTICAL INDUSTRY 2011 in association with THE PRESCRIPTION MEDICINES CODE OF PRACTICE AUTHORITY

16 Meetings, Hospitality and Sponsorship Clear educational content Appropriate venue Subsistence secondary to the meeting Sponsorship clear and open Costs similar to those the attendee would pay Complaints may be made to the Prescription Medicines Code of Practice Authority. pdf pdf

17 Not that far apart? “The fact that a meeting or course has CPD approval does not mean that the arrangements are automatically acceptable under the Code” (ABPI). “You must not ask for or accept any inducement, gift or hospitality which may affect, or be seen to affect, the way you prescribe for, treat or refer patients” (GMC).

18 Summary Medical regulation must not mean that the regulator determines the content of CME/CPD The primary responsibility for keeping up to date through CME/CPD rests with the learner The effectiveness of CME/CPD activity should be evaluated regularly Industry regulators are increasingly aware of the need to avoid competing interests and bias

19 Thank you!


Download ppt "The Changing Regulatory Environment for Industry Support The accreditation bodies’ point of view. Ian Starke (UK)"

Similar presentations


Ads by Google